Education
About Us
Working with TipRanks
Follow Us
Orchestra BioMed Holdings (OBIO)
NASDAQ:OBIO
OBIO Stock Chart & Stats
$4.36
-$0.06(-1.07%)
At close: 4:00 PM EST
$4.36
-$0.06(-1.07%)
Day’s Range― - ―
52-Week Range$2.20 - $5.42
Previous CloseN/A
Volume15.92K
Average Volume (3M)179.96K
Market Cap
$246.19M
Enterprise Value$220.21M
Total Cash (Recent Filing)$95.82M
Total Debt (Recent Filing)$16.04M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Apr 01, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding56,464,730
10 Day Avg. Volume171,395
30 Day Avg. Volume179,963
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)4.47
Price to Sales (P/S)55.83
P/FCF Ratio-2.90
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue78.14
Enterprise Value/Gross Profit84.02
Enterprise Value/Ebitda-2.95
Forecast
1Y Price Target
$12.33Price Target Upside182.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.6
Revenue Forecast (FY)$3.13M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA 92.66% gross margin signals very efficient device-level economics and low direct COGS. Structurally this provides durable operating leverage: as sales scale, high gross margins can absorb R&D and SG&A, improving the company's path to sustainable profitability over months to years.
Strategic Partnerships And Capital RaisedNearly $150M of capital plus deeper collaboration with Medtronic strengthen funding runway, trial execution and future commercial channels. These structural partnerships and financing materially lower development and go‑to‑market risk, improving chances to complete pivotal trials and scale device adoption.
Vivasure Sale Proceeds Boost LiquidityUp to $21M in non‑dilutive proceeds, with ~$11M expected in 2026, meaningfully strengthens near‑term liquidity. This structural cash inflow extends runway, funds clinical and development milestones, and validates the partnership‑driven device development model versus needing immediate dilutive financing.
Bears Say
High LeverageA debt/equity ratio of 6.68 reflects heavy reliance on debt financing, increasing interest burden and refinancing risk. Structurally, high leverage constrains strategic flexibility, raises covenant/default risk, and amplifies downside if cash generation underperforms over the next several quarters.
Declining Revenue And Persistent LossesA declining revenue trend combined with deep negative net and operating margins indicates the company is not yet scaling a profitable business model. Over a multi‑month horizon, continued top‑line weakness plus negative margins means sustained dependence on external funding until revenue growth or structural cost reductions occur.
Weak Operating Cash GenerationOperating cash flow negative versus net losses shows core operations aren’t producing cash. FCF only marginally covers net losses, so the company remains structurally dependent on external financing or asset monetization to fund trials and commercialization, raising dilution and execution risk.
Orchestra BioMed Holdings News
OBIO FAQ
What was Orchestra BioMed Holdings’s price range in the past 12 months?
Orchestra BioMed Holdings lowest stock price was $2.20 and its highest was $5.42 in the past 12 months.
What is Orchestra BioMed Holdings’s market cap?
Orchestra BioMed Holdings’s market cap is $246.19M.
When is Orchestra BioMed Holdings’s upcoming earnings report date?
Orchestra BioMed Holdings’s upcoming earnings report date is Apr 01, 2026 which is in 28 days.
How were Orchestra BioMed Holdings’s earnings last quarter?
Orchestra BioMed Holdings released its earnings results on Nov 18, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.397 by -$0.003.
Is Orchestra BioMed Holdings overvalued?
According to Wall Street analysts Orchestra BioMed Holdings’s price is currently Undervalued.
Does Orchestra BioMed Holdings pay dividends?
Orchestra BioMed Holdings does not currently pay dividends.
What is Orchestra BioMed Holdings’s EPS estimate?
Orchestra BioMed Holdings’s EPS estimate is -0.38.
How many shares outstanding does Orchestra BioMed Holdings have?
Orchestra BioMed Holdings has 56,464,730 shares outstanding.
What happened to Orchestra BioMed Holdings’s price movement after its last earnings report?
Orchestra BioMed Holdings reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.397. Following the earnings report the stock price went up 10.165%.
Which hedge fund is a major shareholder of Orchestra BioMed Holdings?
Currently, no hedge funds are holding shares in OBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orchestra BioMed Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (182.80% Upside)
$12.33 (182.80% Upside)
Blogger Sentiment
Neutral
OBIO Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 165.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.34%
12-Months-Change
Fundamentals
Return on Equity
-166.97%
Trailing 12-Months
Asset Growth
39.15%
Trailing 12-Months
Company Description
Orchestra BioMed Holdings
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
OBIO Stock 12 Month Forecast
Average Price Target
$12.33
▲(182.80% Upside)
Technical Analysis
Cardiff Oncology
―
Greenwich LifeSciences
―
Climb Bio
―
Cognition Therapeutics
―
Pyxis Oncology
―
Ownership Overview
30.75% Insiders
3.88% Mutual Funds
3.66% Other Institutional Investors
58.60% Public Companies and
Individual Investors